Lithium for treatment of neutropenia in glycogen storage disease type Ib.
D000380:Agranulocytosis / Q000188:drug therapy*; D002712:Chlorides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005953:Glycogen Storage Disease Type I / Q000150:complications*; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D007958:Leukocyte Count; D008094:Lithium / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D018021:Lithium Chloride; D009503:Neutropenia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D012874:Skin Diseases, Infectious / Q000188:drug therapy / Q000209:etiology; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D002712:Chlorides; D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D008094:Lithium; D014295:Trimethoprim; D018021:Lithium Chloride; D013420:Sulfamethoxazole; D007654:Ketoconazole